secwatch.observer — SEC 8-K summary
======================================

Issuer:     Biomea Fusion, Inc. (BMEA)
CIK:        0001840439
Form:       8-K
Filed at:   2023-03-28T23:59:59+00:00
Accession:  0001193125-23-082314
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biomea Fusion reports 89% response rate and 1% median HbA1c reduction at 4 weeks for BMF-219 in T2DM Phase II
--------------------------------------------------------------------------------

- Cohort 3 (100 mg BMF-219 without food, n=9) showed 89% response rate, median HbA1c reduction of -1.0% at day 28.
- 56% of Cohort 3 patients achieved >=1.0% HbA1c reduction; placebo (n=4) had median reduction of -0.1% to -0.15%.
- BMF-219 was well-tolerated; no discontinuations, serious AEs, or severe AEs across healthy volunteers and T2DM cohorts.
- Company plans to explore additional dosing periods >4 weeks and potential utility in type 1 diabetes.
- Dose escalation continues; negative food effect observed (3-fold exposure difference between fed and fasted cohorts).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1840439/000119312523082314/0001193125-23-082314-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1840439/000119312523082314/d311150d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-082314

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer